206 related articles for article (PubMed ID: 27807233)
1. Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins.
Wrensch F; Hoffmann M; Gärtner S; Nehlmeier I; Winkler M; Pöhlmann S
J Virol; 2017 Jan; 91(2):. PubMed ID: 27807233
[TBL] [Abstract][Full Text] [Related]
2. Functional Heterogeneity of Mammalian IFITM Proteins against HIV-1.
Marziali F; Delpeuch M; Kumar A; Appourchaux R; Dufloo J; Tartour K; Etienne L; Cimarelli A
J Virol; 2021 Aug; 95(18):e0043921. PubMed ID: 34160255
[TBL] [Abstract][Full Text] [Related]
3. IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.
Yu J; Li M; Wilkins J; Ding S; Swartz TH; Esposito AM; Zheng YM; Freed EO; Liang C; Chen BK; Liu SL
Cell Rep; 2015 Oct; 13(1):145-156. PubMed ID: 26387945
[TBL] [Abstract][Full Text] [Related]
4. Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV.
Wilkins J; Zheng YM; Yu J; Liang C; Liu SL
PLoS One; 2016; 11(6):e0156739. PubMed ID: 27257969
[TBL] [Abstract][Full Text] [Related]
5. IFITM3 Reduces Retroviral Envelope Abundance and Function and Is Counteracted by glycoGag.
Ahi YS; Yimer D; Shi G; Majdoul S; Rahman K; Rein A; Compton AA
mBio; 2020 Jan; 11(1):. PubMed ID: 31964738
[TBL] [Abstract][Full Text] [Related]
6. CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections.
Wetzel KS; Yi Y; Elliott STC; Romero D; Jacquelin B; Hahn BH; Muller-Trutwin M; Apetrei C; Pandrea I; Collman RG
J Virol; 2017 Feb; 91(4):. PubMed ID: 27903799
[TBL] [Abstract][Full Text] [Related]
7. The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity.
Wang Y; Pan Q; Ding S; Wang Z; Yu J; Finzi A; Liu SL; Liang C
J Virol; 2017 Apr; 91(7):. PubMed ID: 28100616
[TBL] [Abstract][Full Text] [Related]
8. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity.
Tartour K; Appourchaux R; Gaillard J; Nguyen XN; Durand S; Turpin J; Beaumont E; Roch E; Berger G; Mahieux R; Brand D; Roingeard P; Cimarelli A
Retrovirology; 2014 Nov; 11():103. PubMed ID: 25422070
[TBL] [Abstract][Full Text] [Related]
9. Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization.
Vzorov AN; Compans RW
J Virol; 2000 Sep; 74(18):8219-25. PubMed ID: 10954518
[TBL] [Abstract][Full Text] [Related]
10. Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs.
Tartour K; Nguyen XN; Appourchaux R; Assil S; Barateau V; Bloyet LM; Burlaud Gaillard J; Confort MP; Escudero-Perez B; Gruffat H; Hong SS; Moroso M; Reynard O; Reynard S; Decembre E; Ftaich N; Rossi A; Wu N; Arnaud F; Baize S; Dreux M; Gerlier D; Paranhos-Baccala G; Volchkov V; Roingeard P; Cimarelli A
PLoS Pathog; 2017 Sep; 13(9):e1006610. PubMed ID: 28957419
[TBL] [Abstract][Full Text] [Related]
11. Small variations in the length of the cytoplasmic domain of the simian immunodeficiency virus transmembrane protein drastically affect envelope incorporation and virus entry.
Manrique JM; Celma CC; Affranchino JL; Hunter E; González SA
AIDS Res Hum Retroviruses; 2001 Nov; 17(17):1615-24. PubMed ID: 11779349
[TBL] [Abstract][Full Text] [Related]
12. Human cytomegalovirus exploits interferon-induced transmembrane proteins to facilitate morphogenesis of the virion assembly compartment.
Xie M; Xuan B; Shan J; Pan D; Sun Y; Shan Z; Zhang J; Yu D; Li B; Qian Z
J Virol; 2015 Mar; 89(6):3049-61. PubMed ID: 25552713
[TBL] [Abstract][Full Text] [Related]
13. Role of Viral Envelope Proteins in Determining Susceptibility of Viruses to IFITM Proteins.
Marceau T; Braibant M
Viruses; 2024 Feb; 16(2):. PubMed ID: 38400030
[TBL] [Abstract][Full Text] [Related]
14. Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction.
Foster TL; Wilson H; Iyer SS; Coss K; Doores K; Smith S; Kellam P; Finzi A; Borrow P; Hahn BH; Neil SJD
Cell Host Microbe; 2016 Oct; 20(4):429-442. PubMed ID: 27640936
[TBL] [Abstract][Full Text] [Related]
15. Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.
Zhao X; Sehgal M; Hou Z; Cheng J; Shu S; Wu S; Guo F; Le Marchand SJ; Lin H; Chang J; Guo JT
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263263
[TBL] [Abstract][Full Text] [Related]
16. IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms.
Wrensch F; Winkler M; Pöhlmann S
Viruses; 2014 Sep; 6(9):3683-98. PubMed ID: 25256397
[TBL] [Abstract][Full Text] [Related]
17. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread.
Compton AA; Bruel T; Porrot F; Mallet A; Sachse M; Euvrard M; Liang C; Casartelli N; Schwartz O
Cell Host Microbe; 2014 Dec; 16(6):736-47. PubMed ID: 25464829
[TBL] [Abstract][Full Text] [Related]
18. Positive and negative modulation of virus infectivity and envelope glycoprotein incorporation into virions by amino acid substitutions at the N terminus of the simian immunodeficiency virus matrix protein.
Manrique JM; Celma CC; Hunter E; Affranchino JL; González SA
J Virol; 2003 Oct; 77(20):10881-8. PubMed ID: 14512538
[TBL] [Abstract][Full Text] [Related]
19. Functional Mapping of Regions Involved in the Negative Imprinting of Virion Particle Infectivity and in Target Cell Protection by Interferon-Induced Transmembrane Protein 3 against HIV-1.
Appourchaux R; Delpeuch M; Zhong L; Burlaud-Gaillard J; Tartour K; Savidis G; Brass A; Etienne L; Roingeard P; Cimarelli A
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355696
[TBL] [Abstract][Full Text] [Related]
20. Conserved molecular signatures in gp120 are associated with the genetic bottleneck during simian immunodeficiency virus (SIV), SIV-human immunodeficiency virus (SHIV), and HIV type 1 (HIV-1) transmission.
Gonzalez MW; DeVico AL; Lewis GK; Spouge JL
J Virol; 2015 Apr; 89(7):3619-29. PubMed ID: 25589663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
